AnaptysBio Inc. (AN6)
XSTU
Real-time Data
06:00 AM
Day's Range
47.9052 wk Range
16.00Overview - AN6 - AnaptysBio Inc.
Key Statistics
Valuation
Enterprise Value
1.26B
P/E (Trailing)
‪-108.13‬
PEG Ratio
‪-2.47‬
Price / Sales (TTM)
‪6.32‬
Price / Book
‪111.95‬
EV / EBITDA
‪18.20‬
Profitability
Operating Margin
‪28.48%‬
Return on Assets
‪-3.63%‬
Return on Equity
‪-35.56%‬
Ownership
Shares Outstanding
29.03M
Price stats
50-Day Avg
‪39.02‬
200-Day Avg
‪26.12‬
Market Cap - AN6 - AnaptysBio Inc.
Peers - AN6 - AnaptysBio Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XSTU.
- AN6XSTUAnaptysBio Inc.1.48BMarket Cap+65.30%52-week change-107.13P/E (Trailing)—Profit Margin
- 6IBXSTUInnovent Biologics Inc.14.71BMarket Cap+5.19%52-week change—P/E (Trailing)‪86.53%‬Profit Margin
- 4KBXSTUKrystal Biotech Inc.8.64BMarket Cap+57.07%52-week change42.50P/E (Trailing)‪54.81%‬Profit Margin
- 2X10XSTUAbivax SA ADR8.59BMarket Cap+36.14%52-week change-20.91P/E (Trailing)‪0.00%‬Profit Margin
- 19XXSTUAxsome Therapeutics, Inc.7.98BMarket Cap+41.14%52-week change-47.55P/E (Trailing)‪92.56%‬Profit Margin
- 30JXSTUIdeaya Biosciences Inc.3.31BMarket Cap+38.45%52-week change-26.67P/E (Trailing)‪-74.75%‬Profit Margin
- BSFAXSTUAni Pharmaceuticals Inc.1.45BMarket Cap-21.26%52-week change16.28P/E (Trailing)‪11.07%‬Profit Margin
Profile Summary - AN6 - AnaptysBio Inc.
About
AnaptysBio Inc. is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. It advances antibody-based drug candidates that modulate immune pathways, including rosnilimab, a PD-1 agonist and pathogenic T cell depleter studied in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
